Lanadelumab Market
Number of pages: 100 | Report Format: PDF | Published date: May 18, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
7.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Age Group and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global lanadelumab market is expected to grow at a revenue CAGR of 7.6% from 2023 to 2031.
Lanadelumab Market Fundamentals
Lanadelumab is a pharmaceutical drug that belongs to a class of medications called monoclonal antibodies. It prevents attacks in individuals with hereditary angioedema (HAE), a rare genetic disorder characterized by recurring swelling in various body parts. Lanadelumab works by inhibiting an enzyme called plasma kallikrein, which is involved in the inflammatory process that leads to HAE attacks. By reducing this enzyme's activity, lanadelumab helps prevent swelling episodes and improve the quality of life for individuals with HAE.
The global lanadelumab industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the lanadelumab market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the lanadelumab market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Lanadelumab Market Dynamics
Hereditary angioedema is a rare genetic disorder, and the prevalence of hereditary angioedema has been increasing globally. As awareness and diagnosis of hereditary angioedema improve, the demand for effective treatments like Lanadelumab is rising. According to the National Center for Biotechnology Information, the global prevalence of hereditary angioedema is about 1 in 10,000 to 1 in 50,000 population. Lanadelumab has demonstrated high efficacy in preventing hereditary angioedema attacks in clinical trials. Its safety profile and convenient dosing regimen once every two or four weeks make it an attractive option for patients and healthcare providers. The dosing frequency of lanadelumab allows for less frequent injections than other hereditary angioedema prophylactic treatments, which typically require more frequent administration. This convenience may lead to improved patient adherence and satisfaction. Lanadelumab’s unique mechanism of action, specifically targeting plasma kallikrein, sets it apart from other hereditary angioedema treatments. Its ability to effectively prevent hereditary angioedema attacks with a different approach positions it as a valuable therapeutic option in the market. As the awareness and understanding of hereditary angioedema improve in other regions, there is a potential for lanadelumab to expand its market presence into previously untapped markets.
However, the high cost of lanadelumab is a major restricting factor of the lanadelumab market. According to the National Center for Biotechnology Information, lanadelumab is available as a single ready-to-use (300 mg/2 mL) solution for $20,538 per vial. Lanadelumab has an average yearly cost of $533,988 and $266,994, with dosing intervals every two and four weeks, respectively. Although lanadelumab has demonstrated a favorable safety profile in clinical trials, ongoing monitoring of long-term safety and potential adverse events is essential. These safety concerns or adverse events reported post-launch could impact its market acceptance.
Lanadelumab Market Ecosystem
Lanadelumab Market, by Age Group
Lanadelumab Market by Age Group
[75744]
The adult segment accounted for the largest revenue share of the lanadelumab market. Hereditary angioedema typically manifests during adolescence or adulthood. Therefore, most individuals diagnosed with Hereditary angioedema and requiring treatment with Lanadelumab are adults. Almost all patients with HAE-C1INH manifest symptoms by the age of 20. Lanadelumab was initially approved for use in individuals aged 12 years and older.
Consequently, it primarily targets the adult population. Lanadelumab is administered as a long-term prophylactic treatment to prevent Hereditary angioedema attacks. Since adults with Hereditary angioedema often require ongoing preventive therapy, they represent a more significant portion of the target population. Clinical trials for Lanadelumab initially focused on adult patients to establish safety and efficacy. Therefore, more data may be available to support its use in adults compared to pediatric patients.
The market segmentation sections provide the lanadelumab market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of industry into subgroups depending on characteristics such as age group, and other factors. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential lanadelumab market demand opportunities.
Lanadelumab Market by Region
The North America region has the largest lanadelumab market size in terms of revenue generation. North America has a relatively high prevalence of Hereditary angioedema compared to other regions. This increased prevalence drives the market's demand for effective treatments such as Lanadelumab. According to the study published in Rare Disease Advisor, in the U.S. around 5,000 to 30,000 annual emergency department admissions took place due to Hereditary angioedema. North America is known for its advanced healthcare infrastructure, including well-established healthcare systems, specialized clinics, and research facilities. This infrastructure supports the development, approval, and distribution of innovative therapies like Lanadelumab. Regulatory bodies in North America, such as the FDA, have rigorous standards for drug approval. These regulatory authorities' successful approval of lanadelumab indicates its safety and efficacy, instilling confidence in healthcare professionals and patients. Increasing awareness about HAE and the availability of treatment options in North America contribute to a higher demand for Lanadelumab. Patient advocacy groups and educational initiatives play a crucial role in raising awareness and supporting access to innovative therapies.
Based on the regions, the global lanadelumab market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of lanadelumab industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level lanadelumab market overview.
Key Components of the Report
Lanadelumab Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Lanadelumab Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Lanadelumab is a pharmaceutical drug that belongs to a class of medications called monoclonal antibodies. It prevents attacks in individuals with hereditary angioedema (HAE), a rare genetic disorder characterized by recurring episodes of swelling in various body parts.
Asia Pacific can be considered the key growth region due to the surge in lanadelumab industry trends in China, Japan, and the Indian subcontinent.
The lanadelumab market is expected to register a revenue CAGR of 7.6% during the forecast period from 2023 to 2031.
While Lanadelumab has gained approval in certain regions, there are still untapped markets where the medication has not been introduced. Expansion into new geographies with a high prevalence of hereditary angioedema provides an opportunity for market players.
Market players invest in R&D activities to enhance the understanding of hereditary angioedema, explore new indications, improve treatment outcomes, and develop next-generation therapies. Continued research helps to strengthen the efficacy and safety profile of lanadelumab.
The key player operating in the global lanadelumab market is Takeda Pharmaceutical Company Limited.
The adult segment dominated the lanadelumab market.
The high cost related to lanadelumab, and the safety concerns related to lanadelumab are some of the restricting factors of the lanadelumab market.
The increasing prevalence of hereditary angioedema globally and the competitive advantage of lanadelumab are some of the major driving factors of the market.
*Insights on financial performance are subject to the availability of information in the public domain